dr. hugo ford on second-line docetaxel in advanced esophagogastric cancer
Published 11 years ago • 287 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
1:49
dr. hugo ford on the phase iii cougar-02 gastroesophageal cancer study
-
1:43
dr. oh on the role of docetaxel in metastatic hormone-sensitive prostate cancer
-
1:17
dr. oh on the safety profile of docetaxel in prostate cancer
-
1:24
dr. higano on docetaxel for hormone-sensitive prostate cancer
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer
-
1:11
dr. daniel petrylak on orteronel (tak-700) plus docetaxel in prostate cancer
-
1:19
comparing abiraterone and docetaxel in prostate cancer treatment
-
0:30
dr. grothey on trastuzumab for gastroesophageal cancer
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
4:52
docetaxel in non-metastatic prostate cancer
-
4:15
docetaxel in metastatic prostate cancer
-
1:01
dr. agarwal on the advantages of docetaxel in prostate cancer
-
55:35
is there still a role for docetaxel in mhspc?
-
0:45
dr. hahn on patients with prostate cancer whom neither docetaxel or abiraterone is an option
-
1:32
dr. hahn discusses abiraterone versus docetaxel in prostate cancer
-
55:35
is there still a role for docetaxel in mhspc?
-
5:42
treatments for post-docetaxel prostate cancer, part ii
-
4:11
second-line treatment for hepatocellular carcinoma
-
1:19
role of the addition of docetaxel to adt in mhspc